1921
Volume 70, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Malaria vaccine RTS,S combined with thrombospondin-related anonymous protein (TRAP) and formulated with AS02A (RTS,S+TRAP/AS02A) is safe and immunogenic in adult humans and rhesus monkeys (). Here, RTS,S+TRAP/AS02A was administered on a 0-, 1-, and 3-month schedule to three cohorts of infant monkeys, along with adult comparators. Cohort 1 evaluated 1/5, 1/2, and full adult doses, with the first dose administration at one month of age; cohort 2 monkeys received full adult doses, with the first dose administration at one versus three months of age; and, cohort 3 compared infants gestated in mothers with or without previous RTS,S/AS02A immunization. Immunization site reactogenicity was mild. Some infants, including the phosphate-buffered saline only recipient, developed transient iron-deficiency anemia, which is considered a result of repeated phlebotomies. All RTS,S+TRAP/AS02A regimens induced vigorous antibody responses that persisted through 12 weeks after the last vaccine dose. Modest lymphoproliferative and ELISPOT (interferon-γ and interleukin-5) responses, particularly to TRAP, approximated adult comparators. RTS,S+TRAP/AS02A was safe and well tolerated. Vigorous antibody production and modest, selective cell-mediated immune responses suggest that RTS,S+TRAP/AS02A may be immunogenic in human infants.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2004.70.499
2004-05-01
2017-11-18
Loading full text...

Full text loading...

/deliver/fulltext/14761645/70/5/0700499.html?itemId=/content/journals/10.4269/ajtmh.2004.70.499&mimeType=html&fmt=ahah

References

  1. Olliaro P, Taylor WR, Rigal J, 2001. Controlling malaria: challenges and solutions. Trop Med Int Health 6 : 922–927.
  2. Guerin PJ, Olliaro P, Nosten F, Druilhe P, Laxminarayan R, Binka F, Kilama WL, Ford N, White NJ, 2002. Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. Lancet Infect Dis 2 : 564–573.
  3. Snow RW, Marsh K, 2002. The consequences of reducing transmission of Plasmodium falciparum in Africa. Adv Parasitol 52 : 235–264.
  4. Hay SI, Were EC, Renshaw M, Noor AM, Ochola SA, Olusanmi I, Alipui N, Snow RW, 2003. Forecasting, warning, and detection of malaria epidemics: a case study. Lancet 361 : 1705–1706.
  5. Ariey F, Robert V, 2003. The puzzling links between malaria transmission and drug resistance. Trends Parasitol 19 : 158–160.
  6. Ballou WR, Kester KE, Heppner DG, 2002. Preerythrocytic malaria vaccines to prevent Plasmodium falciparum malaria. Chem Immunol 80 : 253–261.
  7. Korenromp EL, Williams BG, Gouws E, Dye C, Snow RW, 2003. Measurement of trends in childhood malaria mortality in Africa: an assessment of progress toward targets based on verbal autopsy. Lancet Infect Dis 3 : 349–358.
  8. Kurtzhals JA, Helleberg M, Goka BQ, Akanmori BD, 2003. Severe malaria in west African children. Lancet 361 : 1393.
  9. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, Wellde BT, Garcon N, Krzych U, Marchand M, 1997. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 336 : 86–91.
  10. Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG, Hall T, Krzych U, Delchambre M, Voss G, Dowler MG, Palensky J, Wittes J, Cohen J, Ballou WR, 2001. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis 183 : 640–647.
  11. Doherty JF, Pinder M, Tornieporth N, Carton C, Vigneron L, Milligan P, Ballou WR, Holland CA, Kester KE, Voss G, Momin P, Greenwood BM, McAdam KP, Cohen J, 1999. A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia. Am J Trop Med Hyg 61 : 865–868.
  12. Stoute JA, Kester KE, Krzych U, Wellde BT, Hall T, White K, Glenn G, Ockenhouse CF, Garcon N, Schwenk R, Lanar DE, Sun P, Momin P, Wirtz RA, Golenda C, Slaoui M, Wortmann G, Holland C, Dowler M, Cohen J, Ballou WR, 1998. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J Infect Dis 178 : 1139–1144.
  13. Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE, Ballou WR, Conway DJ, Reece WH, Gothard P, Yamuah L, Delchambre M, Voss G, Greenwood BM, Hill A, McAdam KP, Tornieporth N, Cohen JD, Doherty T, 2001. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358 : 1927–1934.
  14. Rogers WO, Malik A, Mellouk S, Nakamura K, Rogers MD, Szarfman A, Gordon DM, Nussler AK, Aikawa M, Hoffman SL, 1992. Characterization of Plasmodium falciparum sporozoite surface protein 2. Proc Natl Acad Sci USA 89 : 9176–9180.
  15. Sultan AA, Thathy V, Frevert U, Robson KJ, Crisanti A, Nussenzweig V, Nussenzweig RS, Menard R, 1997. TRAP is necessary for gliding motility and infectivity of Plasmodium sporozoites. Cell 90 : 511–522.
  16. Robson KJ, Hall JR, Jennings MW, Harris TJ, Marsh K, New-bold CI, Tate VE, Weatherall DJ, 1988. A highly conserved amino-acid sequence in thrombospondin, properdin and in proteins from sporozoites and blood stages of a human malaria parasite. Nature 335 : 79–82.
  17. Robson KJ, Frevert U, Reckmann I, Cowan G, Beier J, Scragg IG, Takehara K, Bishop DH, Pradel G, Sinden R, 1995. Thrombospondin-related adhesive protein (TRAP) of Plasmodium falciparum: expression during sporozoite ontogeny and binding to human hepatocytes. EMBO J 14 : 3883–3894.
  18. Kohli-Kumar M, 2001. Screening for anemia in children: AAP recommendations–a critique. Pediatrics 108 : E56.
  19. Eden AN, Mir MA, 1997. Iron deficiency in 1- to 3-year-old children. A pediatric failure? Arch Pediatr Adolesc Med 151 : 986–988.
  20. Siegrist CA, 2000. Vaccination in the neonatal period and early infancy. Int Rev Immunol 19 : 195–219.
  21. Siegrist CA, 2001. Neonatal and early life vaccinology. Vaccine 19 : 3331–3346.
  22. Ota MO, Vekemans J, Shlagel-Haueter SE, Fiedling K, Whittle H, Lambert PH, McAdam KP, Siegrist CA, Marchant A, 2004. Hepatitis B immunisation induces higher antibody and memory Th2 responses in new-born infants than in adults. Vaccine 22 : 511–519.
  23. Lalvani A, Moris P, Voss G, Pathan AA, Kester KE, Brookes R, Lee E, Koutsoukos M, Plebanski M, Delchambre M, Flanagan KL, Carton C, Slaoui M, Van Hoecke C, Ballou WR, Hill AV, Cohen J, 1999. Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine. J Infect Dis 180 : 1656–1664.
  24. Elliman D, Bedford H, 2003. Safety and efficacy of combination vaccines. BMJ 326 : 995–996.
  25. McVernon J, Andrews N, Slack MP, Ramsay ME, 2003. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 361 : 1521–1523.
  26. Marcy SM, 2003. Pediatric combination vaccines: their impact on patients, providers, managed care organizations, and manufacturers. Am J Manag Care 9 : 314–320.
  27. Kovarik J, Siegrist CA, 2001. The search for novel adjuvants for early life vaccinations: can “danger” motifs show us the way? Arch Immunol Ther Exp (Warsz) 49 : 209–215.
  28. Fernie S, Wrenshall E, Malcolm S, Bryce F, Arnold DL, 1994. Normative hematologic and serum biochemical values for adult and infant rhesus monkeys (Macaca mulatta) in a controlled laboratory environment. J Toxicol Environ Health 42 : 53–72.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2004.70.499
Loading
/content/journals/10.4269/ajtmh.2004.70.499
Loading

Data & Media loading...

  • Received : 17 Nov 2003
  • Accepted : 19 Jan 2004

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error